Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac

Nanomedicine

Volumn 12, Issue 3, 2017, Pages 195-205

  Sudha, Thangirala ^a   Bharali, Dhruba J ^a   Yalcin, Murat ^a,b   Darwish, Noureldien H E ^a,c   Coskun, Melis Debreli ^a,b   Keating, Kelly A ^a   Lin, Hung Yun ^d   Davis, Paul J ^a,e   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ULUDAG UNIVERSITY   (Turkey)

^c MANSOURA UNIVERSITY   (Egypt)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e ALBANY MEDICAL COLLEGE   (United States)

Author keywords

cisplatin; integrin; nanotetrac; NDAT; tetraiodothyroacetic acid; urinary bladder carcinoma

Indexed keywords

ACETIC ACID DERIVATIVE; CISPLATIN; NANOCARRIER; NANODIAMINOTETRAC; NANOPARTICLE; POLYGLACTIN; TETRAIODOTHYROACETIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER SIZE; CONTROLLED STUDY; COVALENT BOND; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NANOENCAPSULATION; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; BLADDER TUMOR; CANCER TRANSPLANTATION; CELL CULTURE TECHNIQUE; CELL SURVIVAL; CHEMISTRY; DRUG RELEASE; METABOLISM; NUDE MOUSE; PARTICLE SIZE; SURFACE PROPERTY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; FEMALE; HETEROGRAFTS; HUMANS; INTEGRIN ALPHAVBETA3; LACTIC ACID; MICE, NUDE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; PARTICLE SIZE; POLYGLYCOLIC ACID; SURFACE PROPERTIES; URINARY BLADDER NEOPLASMS;

EID: 85010383217     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2016-0315     Document Type: Article

References (35)

1. Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother. Pharmacol. 77(6), 1103-1124 (2016).
2. Matsusaka S, Lenz HJ. Pharmacogenomics of fuorouracil-based chemotherapy toxicity. Expert Opin. Drug Metab. Toxicol. 11(5), 811-821 (2015).
3. Chan ES, Cronstein BN. Mechanisms of action of methotrexate. Bull. Hosp. Jt. Dis. 71(Suppl. 1), S5-S8 (2013).
4. Rivankar S. An overview of doxorubicin formulations in cancer therapy. J. Cancer Res. Ther. 10(4), 853-858 (2014).
5. Barbuti AM, Chen ZS. Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy. Cancers 7(4), 2360-2371 (2015).
6. Ulbrich K, Hola K, Subr V, Bakandritsos A, Tucek J, Zboril R. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem. Rev. 116(9), 5338-5431 (2016).
7. Arosio D, Casagrande C. Advancement in integrin facilitated drug delivery. Adv. Drug Deliv. Rev. 97, 111-143 (2016).
8. Linton SS, Sherwood SG, Drews KC, Kester M. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8(2), 208-222 (2016).
9. Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro. Oncol. 18(1), 27-36 (2016).
10. Soudy R, Byeon N, Raghuwanshi Y, Ahmed S, Lavasanifar A, Kaur K. Engineered peptides for applications in cancer targeted drug delivery and tumor detection. Mini Rev. Med. Chem.16, doi:10.2174 /1389557516666160219121836 (2016) (Epub ahead of print).
11. Yang Y, Yu C. Advances in silica based nanoparticles for targeted cancer therapy. Nanomedicine 12(2), 317-332 (2016).
12. Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted pt(II), agents, nanoparticle delivery, and pt(IV), prodrugs. Chem. Rev. 116(5), 3436-3486 (2016).
13. Wang X, Guo Z. Targeting and delivery of platinum-based anticancer drugs. Chem. Soc. Rev. 42(1), 202-224 (2013).
14. Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nat. Rev. Endocrinol. 12 (2), 111-121 (2016).
15. Lü JM, Wang X, Marin-Muller C et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 9(4), 325-341 (2009).
16. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10 (1), 9-22 (2010).
17. Somanath PR, Ciocea A, Byzova TV. Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem. Biophys. 53(2), 53-64 (2009).
18. Thangirala S, Bharali DJ, Yalcin M et al. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac. Int. J. Nanomed. (2016) (In Press).
19. Bharali DJ, Yalcin M, Davis PJ, Mousa SA. Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine (Lond.) 8 (12), 1943-1954 (2013).
20. Basotra M, Singh SK, Gulati M. Development and validation of a simple and sensitive spectrometric method for estimation of cisplatin hydrochloride in tablet dosage forms: application to dissolution studies. ISRN Anal. Chem. 2013, 936254 (2013).
21. Golla ED, Ayres GH. Spectrophotometric determination of platinum with o-phenylenediamine. Talanta 20 (2), 199-210 (1973).
22. Bergh JJ, Lin HY, Lansing L et al. Integrin αvβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146(7), 2864-2871 (2005).
23. Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu. Rev. Pharmacol. Toxicol. 51, 99-115 (2011).
24. Davis PJ, Glinsky GV, Lin HY et al. Cancer cell gene expression modulated from plasma membrane integrin αvβ3 by thyroid hormone and nanoparticulate tetrac. Front. Endocrinol. (Lausanne) 5, 240 (2014).
25. Yalcin M, Lin HY, Sudha T et al. Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. Horm. Cancer 4(3), 176-185 (2013).
26. Yalcin M, Bharali DJ, Lansing L et al. Tetraidothyroacetic acid (tetrac), and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res. 29(10), 3825-3831 (2009).
27. Mousa SA, Yalcin M, Bharali DJ et al. Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small-cell lung cancer cells in vitro and its growth in xenografts. Lung Cancer 76(1), 39-45 (2012).
28. Glinskii AB, Glinsky GV, Lin HY et al. Modifcation of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8(21), 3562-3570 (2009).
29. Lin HY, Sun M, Tang HY et al. L-Thyroxine vs. 3,5,3 '-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am. J. Physiol. Cell Ph. 296(5), C980-C991 (2009).
30. Saha C, Kaushik A, Das A, Pal S, Majumder D. Anthracycline drugs on modifed surface of quercetin-loaded polymer nanoparticles: a dual drug delivery model for cancer treatment. PLoS ONE 11(5), e0155710 (2016).
31. Composition of matter patent application with cancer chemotherapy encapsulated was fled with the U.S. Patent and Trademark Offce on 06/15/10 (Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists and Formulations and Uses Thereof; application #12/816287, patent #9,220,788 issued). Method of treatment patent application using Nanotetrac with the chemotherapeutic agent encapsulated was fled with the U.S. Patent and Trademark Offce on 11/16/10 (Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists and Formulations and Uses thereof; application #12/947,389, patent #9,289,395 issued).
32. Lee S, Kim J, Shim G et al. Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor. J. Control. Release 164(2), 213-220 (2012).
33. Lin HY, Landersdorfer CB, London D et al. Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. PLoS Comput. Biol. 7(2), e1001073 (2011).
34. Chtourou Y, Aouey B, Kebieche M, Fetoui H. Protective role of naringin against cisplatin induced oxidative stress, infammatory response and apoptosis in rat striatum via suppressing ROS-mediated NF-kappaB and P53 signaling pathways. Chem. Biol. Interact. 239, 76-86 (2015).
35. Sharawy N, Rashed L, Youakim MF. Evaluation of multi-neuroprotective effects of erythropoietin using cisplatin induced peripheral neurotoxicity model. Exp. Toxicol. Pathol. 67 (4) , 315-322 (2015).